INVOSSA Emerging Drug Insight

“INVOSSA Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about INVOSSA for knee osteoarthritis (OA) in the seven major markets. A detailed picture of the INVOSSA for knee osteoarthritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the INVOSSA for knee osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVOSSA market forecast analysis for knee osteoarthritis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in knee osteoarthritis.

Drug Summary

INVOSSA (TG-C) is an allogeneic (donor) cell and gene therapy involving primary human chondrocytes (cartilage cells) and human cells transduced to express the therapeutic growth factor TGF-ß1. INVOSSA (TG-C) is a combination of the two. It has been developed to treat knee osteoarthritis and is delivered via one intra-articular injection into the knee.

Clinical trials held in the US have demonstrated significant improvement in pain relief and function for 2 years and indicators toward the decreased progression of OA and improvements in joint structure. The company has plans for two pivotal Phase III clinical trials in knee OA in the US, first under a Special Protocol Assessment (SPA) agreement reached with the US FDA. In the upcoming US Phase III clinical trial, Kolon TissueGene intends to continue to demonstrate an improvement in pain and function for 2 years. The trial was suspended in 2019, but the clinical hold was lifted later in the year 2020. In addition, the company has designed the trial to seek a disease-modifying osteoarthritis drug (DMOAD) designation for the drug.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the INVOSSA description, mechanism of action, dosage and administration, research and development activities in knee osteoarthritis.
•  Elaborated details on INVOSSA regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the INVOSSA research and development activities in knee osteoarthritis across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around INVOSSA.
•  The report contains forecasted sales of INVOSSA for knee osteoarthritis till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for knee osteoarthritis.
•  The report also features the SWOT analysis with analyst views for INVOSSA in knee osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

INVOSSA Analytical Perspective by DelveInsight

• In-depth INVOSSA Market Assessment

This report provides a detailed market assessment of INVOSSA for knee osteoarthritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• INVOSSA Clinical Assessment

The report provides the clinical trials information of INVOSSA for knee osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for knee osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVOSSA dominance.
•  Other emerging products for knee osteoarthritis are expected to give tough market competition to INVOSSA and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVOSSA in knee osteoarthritis.
•  Our in-depth analysis of the forecasted sales data of INVOSSA from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVOSSA in knee osteoarthritis.

Key Questions

•  What is the product type, route of administration and mechanism of action of INVOSSA?
•  What is the clinical trial status of the study related to INVOSSA in knee osteoarthritis and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the INVOSSA development?
•  What are the key designations that have been granted to INVOSSA for knee osteoarthritis?
•  What is the forecasted market scenario of INVOSSA for knee osteoarthritis?
•  What are the forecasted sales of INVOSSA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available and how are these giving competition to INVOSSA for knee osteoarthritis?
•  Which are the late-stage emerging therapies under development for the treatment of knee osteoarthritis?